Evidence map›Paper›PMID 35677168›Full record

ArticleFrontiers in oncology2022

Neurotropic Cutaneous Malignancies: Case Report on Keratinocyte Derived Malignancies of the Head and Neck With Perineural Invasion.

Grace Sora Ahn, Brian Hinds, Frederic Kolb, Amy K Reisenauer, Seaver L Soon, Ali R Sepahdari, Kathryn B Bollin, Soo J Park

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Grace Sora AhnDepartment of Dermatology, University of California, San Diego, La Jolla, CA, United States.
Brian HindsDepartment of Dermatology, University of California, San Diego, La Jolla, CA, United States.
Frederic KolbDepartment of Plastic Surgery, University of California, San Diego, La Jolla, CA, United States.
Amy K ReisenauerPrivate Practitioner, Kihei, HI, United States.
Seaver L SoonPrivate Practitioner, San Diego, CA, United States.
Ali R SepahdariDiagnostic Neuroradiology, Scripps Clinic Medical Group, La Jolla, CA, United States.
Kathryn B BollinDivision of Hematology and Oncology, Scripps MD Anderson Cancer Center, La Jolla, CA, United States.
Soo J ParkMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
University of California, San Diego · USAmerican Association of Nurse Practitioners · USPacific Disaster Center · USScripps Clinic Medical Group · USScripps MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The recent addition of immunotherapy as a treatment modality to surgery and radiation has vastly improved disease control for patients with keratinocyte-derived carcinomas (KCs) that are incurable with local therapies alone. With the advent of immune checkpoint inhibitors (ICPis) in non-melanoma skin cancers comes diagnostic and therapeutic challenges when considering treatment strategies for patients presenting with clinical perineural invasion (cPNI) of locally advanced KC of the head and neck. Objectives: We report four cases that convey the diagnostic and therapeutic complexity of managing patients with neuropathic symptoms from cutaneous neurotropic carcinomas of the head and neck. We also discuss an updated review regarding immunotherapies and perineural invasion within KC management. Conclusion: Patients presenting with symptoms suspicious for cPNI warrant an expanded diagnostic evaluation to correlate neurological findings with neurotropic spread of disease. While nerve biopsies can be precarious in sensitive areas, a history of skin cancer and clinical presentation suggestive of neurotropism may be enough to pursue timely management in the form of surgery, radiation, and/or systemic therapy given each patient's individual priorities, comorbidities, and prognosis. When adding ICPi as a treatment modality for patients with disease not amenable to local therapies, the potential for immune-related adverse events must be considered. A multi-disciplinary review and approach to the management of patients with KC and cPNI is essential for obtaining optimal patient outcomes.

Indexed as

basal cell carcinomacutaneous oncologycutaneous squamous cell carcinomaimmune checkpoint inhibitorsimmunotherapyneurotropic cutaneous malignanciesnon-melanoma skin cancerperineural invasion

Identifiers

PMID35677168
PMCPMC9169718
OpenAlexW4281387734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.